Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Pts with R/R LBCL had rapid and durable responses with liso-cel, a CD19-directed chimeric antigen receptor (CAR) T cell therapy. Previous qualitative research showed high perceptions of unmet pretreatment needs and largely positive pt experiences immediately after liso-cel infusion (Interviews 1-3; Siddiqi et al. Blood 2020;136 (suppl 1):22-23). We expanded our study to explore pt-perceived benefits and drawbacks after liso-cel treatment, up to 3 months.